Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 718946, 7 pages
http://dx.doi.org/10.1155/2014/718946
Research Article

Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls

1Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran 1417755469, Iran
2Endocrinology and Metabolism Research Center (EMRC), Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran 1411413137, Iran
3Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran
4Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran
5Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran
6Department of Public Health, Alborz University of Medical Sciences, Karaj 3139614171, Iran
7Department of Epidemiology, Iran University of Medical Sciences, Tehran 1449614535, Iran
8Department of Community and Preventive Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran
9Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari 4817844718, Iran
10Department of Pathology, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran 1419733151, Iran
11Farmanfarmaian Health Center, Tehran University of Medical Sciences, Tehran 1318618311, Iran

Received 6 February 2014; Revised 14 May 2014; Accepted 14 May 2014; Published 4 June 2014

Academic Editor: Robin Vos

Copyright © 2014 Azam Roohi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factor β (TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-β levels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-β were measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-β was significantly lower in type 1 diabetic patients ( ). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-β levels were lower in type 1 diabetic patients.